Your Health, We Care
Release date: 2024-08-09 13:45:51 Recommended: 160
Exkivity was granted accelerated FDA approval in 2021 based on results from the clinical trial NCT02716116. It is used with the Oncomine Dx Target Test, which identifies patients with exon 20 insertion mutations.
Exkivity is mainly metabolized by hepatic cytochrome P450 (CYP) 3A4. Concomitant use with CYP3A4 inhibitors or inducers may alter the plasma concentration and efficacy of Exkivity.
To ensure the safe use of Exkivity, patients should inform their doctor about other medications they are taking, including prescription medications, over-the-counter medications, and supplements, before use.
Coadministration of Exkivity with strong or moderate CYP3A inhibitors increased Exkivity plasma concentrations, which may increase the risk of adverse reactions, including QTc interval prolongation.
Coadministration of Exkivity with strong or moderate CYP3A inducers decreased Exkivity plasma concentrations, which may reduce Exkivity anti-tumor activity.
Avoid concomitant use of strong or moderate CYP3A inhibitors with Exkivity. If concomitant use of moderate CYP3A inhibitors cannot be avoided, reduce the Exkivity dose and monitor the QTc interval more frequently with ECGs.
Avoid concomitant use of strong or moderate CYP3A inducers with Exkivity.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
